Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Opko Health Inc’s stock clocked out at $1.43, up 1.42% from its previous closing price of $1.41. In other words, the price has increased by $1.42 from its previous closing price. On the day, 1.8 million shares were traded. OPK stock price reached its highest trading level at $1.44 during the session, while it also had its lowest trading level at $1.4.
Ratios:
To gain a deeper understanding of OPK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.02 and its Current Ratio is at 3.41. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.29.
On June 29, 2023, Barrington Research Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $2. On December 15, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $3.H.C. Wainwright initiated its Buy rating on December 15, 2022, with a $3 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 08 ’25 when FROST PHILLIP MD ET AL bought 675,000 shares for $1.32 per share. The transaction valued at 891,000 led to the insider holds 214,676,448 shares of the business.
FROST PHILLIP MD ET AL bought 125,000 shares of OPK for $169,712 on Apr 10 ’25. The CEO & Chairman now owns 214,001,448 shares after completing the transaction at $1.36 per share. On Apr 08 ’25, another insider, FROST PHILLIP MD ET AL, who serves as the CEO & Chairman of the company, bought 125,000 shares for $1.48 each. As a result, the insider paid 184,650 and bolstered with 213,876,448 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OPK now has a Market Capitalization of 1135109632 and an Enterprise Value of 1263569408. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.71 while its Price-to-Book (P/B) ratio in mrq is 0.86. Its current Enterprise Value per Revenue stands at 1.903 whereas that against EBITDA is -7.31.
Stock Price History:
The Beta on a monthly basis for OPK is 1.49, which has changed by -0.089171946 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, OPK has reached a high of $2.04, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 5.47%, while the 200-Day Moving Average is calculated to be -2.96%.
Shares Statistics:
It appears that OPK traded 2.80M shares on average per day over the past three months and 1925290 shares per day over the past ten days. A total of 779.78M shares are outstanding, with a floating share count of 358.61M. Insiders hold about 54.82% of the company’s shares, while institutions hold 27.86% stake in the company. Shares short for OPK as of 1756425600 were 32466072 with a Short Ratio of 11.58, compared to 1753920000 on 32768192. Therefore, it implies a Short% of Shares Outstanding of 32466072 and a Short% of Float of 6.9699995.
Earnings Estimates
The market rating of Opko Health Inc (OPK) is currently shaped by the ongoing analysis conducted by 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.27 and -$0.43 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.35, with 1 analysts recommending between -$0.35 and -$0.35.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $166.74M. It ranges from a high estimate of $167.7M to a low estimate of $165.7M. As of the current estimate, Opko Health Inc’s year-ago sales were $173.6MFor the next quarter, 5 analysts are estimating revenue of $168.68M. There is a high estimate of $175.4M for the next quarter, whereas the lowest estimate is $152.5M.
A total of 5 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $649.8M, while the lowest revenue estimate was $625.76M, resulting in an average revenue estimate of $642.17M. In the same quarter a year ago, actual revenue was $713.1MBased on 6 analysts’ estimates, the company’s revenue will be $637.85M in the next fiscal year. The high estimate is $738.8M and the low estimate is $567.1M.
